Literature DB >> 12778463

Role of Toll-like receptors in costimulating cytotoxic T cell responses.

Katrin Schwarz1, Tazio Storni, Vania Manolova, Arnaud Didierlaurent, Jean-Claude Sirard, Peter Röthlisberger, Martin F Bachmann.   

Abstract

Stimulation of Toll-like receptors (TLR) by pathogen-derived compounds leads to activation of APC, facilitating the induction of protective immunity. This phenomenon is the basis of most adjuvant formulations currently in development. Here, we tested the ability of TLR2, 3, 4, 5, 7 and 9 signaling to enhance CTL responses upon vaccination with virus-like particles. Stimulation of TLR2 and 4 failed to increase CTL responses, whereas ligands for TLR3, 5 and 7 exhibited moderate adjuvant function. In contrast, stimulation of TLR9 dramatically increased CTL responses, indicating that ligands for TLR9 are likely to be the most promising candidates for the development of novel adjuvant formulations for stimulating CTL responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12778463     DOI: 10.1002/eji.200323919

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  48 in total

1.  Enhanced antigen processing of flagellin fusion proteins promotes the antigen-specific CD8+ T cell response independently of TLR5 and MyD88.

Authors:  John T Bates; Aaron H Graff; James P Phipps; Jason M Grayson; Steven B Mizel
Journal:  J Immunol       Date:  2011-04-22       Impact factor: 5.422

2.  Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides.

Authors:  Arthur M Krieg
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

3.  Differential ability of surface and endosomal TLRs to induce CD8 T cell responses in vivo.

Authors:  Rajakumar Mandraju; Sean Murray; James Forman; Chandrashekhar Pasare
Journal:  J Immunol       Date:  2014-03-31       Impact factor: 5.422

4.  Factors governing the activation of adoptively transferred donor T cells infused after allogeneic bone marrow transplantation in the mouse.

Authors:  Nadira Durakovic; Vedran Radojcic; Mario Skarica; Karl B Bezak; Jonathan D Powell; Ephraim J Fuchs; Leo Luznik
Journal:  Blood       Date:  2007-01-16       Impact factor: 22.113

Review 5.  Exploiting dendritic cells for active immunotherapy of cancer and chronic infections.

Authors:  David W O'Neill; Nina Bhardwaj
Journal:  Mol Biotechnol       Date:  2007-06       Impact factor: 2.695

6.  Genetic variation in C57BL/6 ES cell lines and genetic instability in the Bruce4 C57BL/6 ES cell line.

Authors:  Elizabeth D Hughes; Yun Yan Qu; Suzanne J Genik; Robert H Lyons; Christopher D Pacheco; Andrew P Lieberman; Linda C Samuelson; Igor O Nasonkin; Sally A Camper; Margaret L Van Keuren; Thomas L Saunders
Journal:  Mamm Genome       Date:  2007-09-09       Impact factor: 2.957

Review 7.  Development of TLR9 agonists for cancer therapy.

Authors:  Arthur M Krieg
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

8.  Nanoparticle conjugation of CpG enhances adjuvancy for cellular immunity and memory recall at low dose.

Authors:  Alexandre de Titta; Marie Ballester; Ziad Julier; Chiara Nembrini; Laura Jeanbart; André J van der Vlies; Melody A Swartz; Jeffrey A Hubbell
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-18       Impact factor: 11.205

Review 9.  Flagellin as an adjuvant: cellular mechanisms and potential.

Authors:  Steven B Mizel; John T Bates
Journal:  J Immunol       Date:  2010-11-15       Impact factor: 5.422

10.  Antigen kinetics determines immune reactivity.

Authors:  Pål Johansen; Tazio Storni; Lorna Rettig; Zhiyong Qiu; Ani Der-Sarkissian; Kent A Smith; Vania Manolova; Karl S Lang; Gabriela Senti; Beat Müllhaupt; Tilman Gerlach; Roberto F Speck; Adrian Bot; Thomas M Kündig
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-24       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.